title: Invasive pulmonary aspergillosis with hematological malignancy caused by Aspergillus terreus and in vitro susceptibility of A. terreus isolate to micafungin.
abstract: A 35-year-old man developed invasive pulmonary aspergillosis (IPA) with severe neutropenia after umbilical cord stem cell transplantation for chronic myelogenous leukemia. Filamentous fungus isolated from his sputum was identified as Aspergillus terreus. Despite systemic amphotericin B (AMPH) administration, IPA progressed. However, intravenous administration of micafungin (MCFG) and oral itraconazole improved clinical data and symptoms, although he later died of massive hemoptysis. Examination of the in vitro susceptibility of this A. terreus isolate to MCFG revealed a good minimum inhibitory concentration and good time-kill assay results compared to AMPH. Thus, MCFG might be useful for IPA caused by A. terreus.
authors.affiliation: Department of Infectious Diseases, Oita University Faculty of Medicine. issei@med.oita-u.ac.jp
authors.forename: Issei
authors.initials: I
authors.lastname: Tokimatsu
authors.forename: Hisako
authors.initials: H
authors.lastname: Kushima
authors.forename: Atsuko
authors.initials: A
authors.lastname: Iwata
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Hashinaga
authors.forename: Kenji
authors.initials: K
authors.lastname: Umeki
authors.forename: Minoru
authors.initials: M
authors.lastname: Ohama
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kohno
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishii
authors.forename: Kenji
authors.initials: K
authors.lastname: Kishi
authors.forename: Masao
authors.initials: M
authors.lastname: Ogata
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Hiramatsu
authors.forename: Tetsunori
authors.initials: T
authors.lastname: Saikawa
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Kadota
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology*; D001230:Aspergillus / Q000187:drug effects / Q000472:pathogenicity; D004359:Drug Therapy, Combination; D054714:Echinocandins; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy; D055666:Lipopeptides; D008074:Lipoproteins / Q000494:pharmacology* / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D000077551:Micafungin; D009503:Neutropenia / Q000150:complications; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D010456:Peptides, Cyclic / Q000494:pharmacology* / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D033581:Stem Cell Transplantation / Q000009:adverse effects
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D017964:Itraconazole; D000077551:Micafungin